IXHL (Incannex Healthcare) Current Deferred Revenue: $0.03 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IXHL Incannex Healthcare Inc IXHL
32 GF Score
Price $2.95
! 2 Warning Signs
View Full Analysis

What is Incannex Healthcare Current Deferred Revenue?

Incannex Healthcare IXHL -5.45% 32 Current Deferred Revenue is $0.03 Mil as of Mar. 2026. GuruFocus rates IXHL with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Incannex Healthcare's current deferred revenue for the quarter that ended in Mar. 2026 was $0.03 Mil.

Incannex Healthcare Current Deferred Revenue Related Terms

Incannex Healthcare Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Incannex Healthcare's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incannex Healthcare Current Deferred Revenue Chart

Incannex Healthcare Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.09 0.03

Incannex Healthcare Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.03 0.03
IXHL
32GF Score
Incannex Healthcare Inc IXHL
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.03 Mil mean?
Incannex Healthcare (IXHL) has a Current Deferred Revenue of $0.03 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Incannex Healthcare and its competitors.
Is Incannex Healthcare's Current Deferred Revenue too high?
Incannex Healthcare's current Current Deferred Revenue is $0.03 Mil. Overall, Incannex Healthcare has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Incannex Healthcare's Current Deferred Revenue compare to ETST and SCYX?
Incannex Healthcare's Current Deferred Revenue of $0.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Incannex Healthcare and its competitors. Incannex Healthcare's current Current Deferred Revenue is $0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incannex Healthcare stock overvalued right now?
Incannex Healthcare (IXHL) has a current Current Deferred Revenue of $0.03 Mil. The current Current Deferred Revenue is $0.03 Mil. Incannex Healthcare's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Incannex Healthcare (IXHL), the current Current Deferred Revenue is $0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Incannex Healthcare Business Description

Address 8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
32GF Score

Get the complete analysis for IXHL

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.95
Price